RT Journal Article
SR Electronic
T1 Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22269422
DO 10.1101/2022.02.07.22269422
A1 Eckold, Clare
A1 van Doorn, Cassandra L.R.
A1 Ruslami, Rovina
A1 Ronacher, Katharina
A1 Riza, Anca-Lelia
A1 van Veen, Suzanne
A1 Lee, Ji-Sook
A1 Kumar, Vinod
A1 Kerry-Barnard, Sarah
A1 Malherbe, Stephanus T.
A1 Kleynhans, Léanie
A1 Stanley, Kim
A1 Joosten, Simone A.
A1 Critchley, Julia A
A1 Hill, Philip C.
A1 van Crevel, Reinout
A1 Wijmenga, Cisca
A1 Haks, Mariëlle C.
A1 Ioana, Mihai
A1 Alisjahbana, Bachti
A1 Walzl, Gerhard
A1 Ottenhoff, Tom H. M.
A1 Dockrell, Hazel M.
A1 Vianello, Eleonora
A1 Cliff, Jacqueline M.
A1 the TANDEM Consortium
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22269422.abstract
AB Background People with diabetes are more likely to develop tuberculosis (TB) and to have poor TB treatment outcomes than those without. We previously showed that blood transcriptomes in people with TB-diabetes (TB-DM) co-morbidity have excessive inflammatory and reduced interferon responses at TB diagnosis. It is unknown whether this persists through treatment, potentially underlying adverse outcomes.Methods Pulmonary TB patients were recruited in South Africa, Indonesia and Romania, and classified as having TB-DM, TB with prediabetes, TB-related hyperglycaemia or uncomplicated TB, based on glycated haemoglobin (HbA1c) concentration at TB diagnosis and after 6 months of TB treatment. Gene expression in blood samples collected at diagnosis and at regular intervals throughout treatment was measured by unbiased RNA-Seq and targeted Multiplex Ligation-dependent Probe Amplification.Results Gene expression was modulated by TB treatment in all groups but to different extents, such that differences remained in people with TB-DM relative to TB-only throughout, including genes involved in innate responses, anti-microbial immunity and the inflammasome. People with prediabetes or with TB-related hyperglycaemia had gene expression more similar to people with TB-DM than TB-only throughout treatment. The overall pattern of change was similar across clinical groups irrespective of glycaemic index, permitting models predictive of TB treatment to be developed.Conclusions The exacerbated transcriptome changes seen in TB-DM take longer to resolve during TB treatment, indicating that prolonged treatment or host-directed therapy may be needed to improve TB treatment outcomes. Development of transcriptome-based biomarker signatures of TB-treatment response should include people with diabetes to be useful across populations.Key Points Host blood transcriptomes are altered in tuberculosis, and further altered with diabetes co-morbidity. We have shown that there is similar resolution of transcriptomes through treatment, but with differing magnitude and kinetics in TB patients with or without diabetes.Competing Interest StatementGW has patents about methods of tuberculosis diagnosis and tuberculosis biomarkers which are unrelated to the current study. No other authors have any declared conflicts of interest.Funding StatementThe research leading to these results, as part of the TANDEM Consortium, has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant Agreement no. 305279.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by LSHTM Observational Research Ethics Committee (6449/July2013), SUN Health Research Ethics Committee (N13/05/064/July2013), UNPAD Health Research Ethics Committee (377/UN6.C2.1.2/ KEPK/PN/2012), and UMFCV Committee of Ethics and Academic and Scientific Deontology (94/September2013).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNASeq data will be available online at NCBI GEO once manuscript is published, Accession number GSE193978. dcRT-MLPA data are available upon reasonable request to the authors.